Phone Interview Research Study AL, ATTR and AA Patients
Phone interview research for patients diagnosed with Amyloid Light-Chain(AL), Transyretin (TTR), or Amyloid Protein (AA) Systemic Amyloidosis
The purpose of this phone interview research study is to gather information about the symptoms and experiences of patients with Amyloid Light-Chain (AL), Transthyretin (TTR), or Amyloid A Protein (AA) Systemic Amyloidosis, in order to develop a questionnaire for future research studies. The interview would last approximately 75 minutes, and you would be compensated for your time. There is no medication administration involved with this study. This study will be conducted by ICON, a health research organization. This study is sponsored by GlaxoSmithKline. Please note that GlaxoSmithKline will not receive any identifying information, and any information that you provide will be reported in a way that protects your privacy and anonymity.
Contact:
If you live in the United States and would like more information about this study, please email Kelly Lipman at 0018-0665-AmyloidosisQual@iconplc.com or call 1-866-893-0282.
- Categories
- Lastest Posts
- FDA Approves Attruby™ (acoramidis) for the Treatment of ATTR-CM: A New Option for Patients
- ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care
- The More Things Change, the More They Stay the Same
- The Inflation Reduction Act: The Devil is in the Details for Patients with Rare Diseases
